Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H1 2018

February 2018 | 59 pages | ID: F4128534DF4EN
Global Markets Direct

Abstracts

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H1 2018

SUMMARY

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family. This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. Diseases associated with FGF2 include corneal neovascularization and pulmonary capillary hemangiomatosis.

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 2 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Metabolic Disorders, Ophthalmology, Central Nervous System, Immunology, Musculoskeletal Disorders and Respiratory which include indications Breast Cancer, Critical Limb Ischemia, Melanoma, Pancreatic Cancer, Achondroplasia, Age Related Macular Degeneration, Angina (Angina Pectoris), Bone Disorders, Cancer Pain, Colon Cancer, Diabetic Macular Edema, Gallbladder Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Intermittent Claudication, Lung Cancer, Lymphoma, Osteoporosis, Ovarian Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Proliferative Diabetic Retinopathy (PDR), Prostate Cancer, Retinal Vein Occlusion and Rheumatoid Arthritis.

The latest report Fibroblast Growth Factor 2 - Pipeline Review, H1 2018, outlays comprehensive information on the Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
• The report reviews Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Overview
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Companies Involved in Therapeutics Development
ID Pharma Co Ltd
Kringle Pharma Inc
Ohr Pharmaceutical Inc
Ribomic Inc
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Drug Profiles
Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DVC-10101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit FGF-2 for Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oncolytic Virus to Activate FGF2 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
squalamine lactate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-764 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Dormant Products
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Discontinued Products
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Product Development Milestones
Featured News & Press Releases
Jan 05, 2018: Ohr Pharmaceutical Announces Efficacy Results from the MAKO Study in Wet-AMD
Apr 10, 2017: Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD
May 02, 2016: Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee
Apr 27, 2016: Ohr Pharmaceutical Announces Presentation on Squalamine Lactate at the 2016 Association for Research in Vision and Ophthalmology Conference in Seattle, WA
Apr 18, 2016: Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program
Mar 29, 2016: Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program
Nov 16, 2015: Ohr Pharmaceutical Presents New Data From OHR-102 Phase II IMPACT Study in Wet-AMD at American Academy of Ophthalmology Annual Meeting
Nov 12, 2015: Ohr Pharmaceutical Announces Submission of a Special Protocol Assessment and Upcoming Presentation on OHR-102 at American Academy of Ophthalmology
Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion
May 07, 2015: Ohr Pharmaceutical Presents Data From OHR-102 Phase II IMPACT Study in Wet-AMD at ARVO Conference
Apr 30, 2015: Ohr Pharmaceutical to Present at the 2015 Association for Research in Vision and Ophthalmology Conference in Denver, CO
Mar 27, 2015: Ohr Pharmaceutical Announces Final Topline Data From OHR-102 Phase II IMPACT Study in Wet-AMD
Mar 02, 2015: Ohr Pharmaceutical Announces Additional Positive Anatomic Data From the OHR-102 IMPACT Study Interim Analysis Presented at Annual Macula Society Meeting
Oct 20, 2014: Ohr Pharmaceutical Announces New Positive Anatomic and Visual Acuity Data on OHR-102 (Squalamine Eye Drops) IMPACT Study Presented at the 2014 American Academy of Ophthalmology Scientific Meeting
Oct 14, 2014: Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by ID Pharma Co Ltd, H1 2018
Pipeline by Kringle Pharma Inc, H1 2018
Pipeline by Ohr Pharmaceutical Inc, H1 2018
Pipeline by Ribomic Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

ID Pharma Co Ltd
Kringle Pharma Inc
Ohr Pharmaceutical Inc
Ribomic Inc